Goldman Sachs Downgrades Kinder Morgan to Sell
Goldman Sachs analyst Michael Lapides downgrades Kinder Morgan (NYSE:KMI) from Neutral to Sell.
Truist Securities Initiates Coverage On Oatly Group with Buy Rating, Announces Price Target of $35
Truist Securities analyst Bill Chappell initiates coverage on Oatly Group (NASDAQ:OTLY) with a Buy rating and announces Price Target of $35.
Guggenheim Initiates Coverage On Oatly Group with Buy Rating, Announces Price Target of $32
Guggenheim analyst Laurent Grandet initiates coverage on Oatly Group (NASDAQ:OTLY) with a Buy rating and announces Price Target of $32.
Citigroup Upgrades CRISPR Therapeutics to Neutral, Raises Price Target to $132
Citigroup analyst Yigal Nochomovitz upgrades CRISPR Therapeutics (NASDAQ:CRSP) from Sell to Neutral and raises the price target from $55 to $132.
Telsey Advisory Group Maintains Outperform on Vintage Wine Estates, Raises Price Target to $16
Telsey Advisory Group analyst Dana Telsey maintains Vintage Wine Estates (NASDAQ:VWE) with a Outperform and raises the price target from $15 to $16.
Raymond James Upgrades EnLink Midstream to Outperform, Announces $7.5 Price Target
Raymond James analyst Justin Jenkins upgrades EnLink Midstream (NYSE:ENLC) from Market Perform to Outperform and announces $7.5 price target.
Long-awaited Novavax’s COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection
Novavax Inc (NASDAQ:NVAX) has finally completed its U.S. Phase 3 trial for its protein-based COVID-19 vaccine candidate. Overall efficacy in the…
Raymond James Upgrades Chipotle Mexican Grill to Strong Buy
Raymond James analyst Brian Vaccaro upgrades Chipotle Mexican Grill (NYSE:CMG) from Outperform to Strong Buy.
SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Lowers Price Target to $200
SVB Leerink analyst Geoffrey Porges maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Market Perform and lowers the price target from $250 to $200.
BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages
BiomX Inc. (NYSE:PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today